Dublin, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The "Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
The global CD3 antibodies market is on a growth trajectory, expected to surpass USD 5 billion by 2028. CD3 antibodies play a crucial role in immune system regulation, making them promising candidates for therapeutic applications in various diseases. Over the years, several CD3 antibodies and anti-CD3 antibodies have been developed to modulate CD3 activity, resulting in a dynamic market with unexplored potential.
The market history saw the approval and withdrawal of pioneering CD3 antibodies like Muromonab-CD3 and Removab. However, subsequent CD3 antibodies with technological advancements have gained regulatory approvals from the FDA and EMA. Among these, Blincyto (CD19 CD3) has shown exceptional commercial success in the treatment of acute lymphoblastic leukemia, generating substantial revenue.
Other CD3 antibodies, approved more recently, are striving to expand their market presence by seeking approvals in additional regions. Their approval in limited regions has constrained their sales and market share. Notably, these antibodies were approved under the FDA's accelerated approval program and the EMA's conditional marketing approval program, awaiting further approvals.
In clinical development, CD3 antibodies primarily target various cancer indications. The trend of bispecific antibodies, specifically T cell engagers, is evident among CD3 antibody candidates, mirroring the mechanism of action of Blincyto and other approved CD3 antibodies. Prominent pharmaceutical companies like Lindis Biotech, BioAtla, AstraZeneca, Regeneron, and Amgen are actively involved in the development of CD3 bispecific T cell engagers.
The market's growth is driven by several factors, including the increasing market value of CD3 antibodies due to ongoing approvals and introductions of new antibodies. Additionally, the involvement of major pharmaceutical corporations enhances the success and financial returns associated with leading CD3 antibodies. Proprietary platforms have played a pivotal role in the development of unique CD3 T cell engagers, enabling the creation of novel antibodies for rare indications with regulatory benefits like orphan drug designation. The global CD3 antibody market holds significant untapped potential, making it a promising domain for exploration.
Key Topics Covered
1. Research Methodology
2. Introduction To CD3 Directed Drugs
2.1 Overview
2.2 History & Evolution of CD3 Directed Drugs
3. Mechanism of Action of CD3 Antibodies
3.1 As Immunosuppressive Therapy
3.2 As Immune Activation Therapy
4. Application of CD3 Antibodies By Indication
4.1 Cancer
4.2 Inflammatory & Autoimmune Conditions
5. Global CD3 Antibodies Market & Clinical Trials Outlook
5.1 Current Market Trends, Developments & Clinical Trials Assessment
5.2 Sales Analysis
5.3 Future Market Opportunities
6. CD3 Targeting Antibodies Market Landscape by Region
6.1 US
6.2 EU
6.3 Canada
6.4 UK
6.5 Japan
7. Approved CD3 Antibody Dosage, Patent, Price & Sales Insight
7.1 Blincyto - 1st Approved CD3 Antibody
7.2 Kimmtrak - 2nd Approved CD3 Antibody
7.3 Tecvayli - 3rd Approved CD3 Antibody
7.4 Others (6 More CD3 Antibodies)
8. Global CD3 Antibodies Clinical Trials Overview
8.1 By Company
8.2 By Country
8.3 By Indication
8.4 By Phase
8.5 By Patient Segment
9. Global CD3 Antibodies Clinical Trials Insight By Company, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-III
9.7 Preregistration
10. Marketed CD3 Antibodies Clinical Insight By Company & Indication
11. Global CD3 Inhibitors Market Dynamics
11.1 Drivers & Opportunities
11.2 Challenges & Restraints
12. Competitive Landscape
12.1 Abpro Therapeutics
12.2 Adagene
12.3 Amgen
12.4 Astellas Pharma
12.5 Beijing Mabworks Biotech
12.6 BioAtla
12.7 Genentech
12.8 Genmab
12.9 Harbour BioMed
12.10 Harpoon Therapeutics
12.11 IGM Biosciences
12.12 Immunocore
12.13 Integral Molecular
12.14 ITabMed
12.15 Janssen Research & Development
12.16 Janux Therapeutics
12.17 KeyMed Biosciences
12.18 Light Chain Bioscience
12.19 Linton Pharm
12.20 MacroGenics
12.21 Memorial Sloan-Kettering Cancer Center
12.22 Pfizer
12.23 Qilu Pharmaceutical
12.24 Regeneron Pharmaceuticals
12.25 Roche
12.26 Sichuan Baili Pharmaceutical
12.27 SystImmune
12.28 Takeda
12.29 Xencor
12.30 Zymeworks
For more information about this report visit https://www.researchandmarkets.com/r/a01fzb
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
